What do systematic reviews say?

Avalglucosidase alfa vs alglucosidase alfa

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 100 participants
  Moderate

Avalglucosidase alfa vs alglucosidase alfa

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 100 participants
  Moderate

Avalglucosidase alfa vs alglucosidase alfa

Avalglucosidase alfa showed no clear difference in infusion reactions compared with alglucosidase alfa (low certainty).

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  RR 0.78 [0.42, 1.45]
  1 study · 100 participants
  Low

Alglucosidase alfa vs placebo

The review found no eligible studies for this question.

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Avalglucosidase alfa vs alglucosidase alfa

The review found no eligible studies for this question.

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Avalglucosidase alfa vs alglucosidase alfa

The review found no eligible studies for this question.

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Avalglucosidase alfa vs alglucosidase alfa

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 100 participants
  Low

Avalglucosidase alfa vs alglucosidase alfa

Avalglucosidase alfa showed no clear difference in treatment‐related AEs: total treatment‐emergent adverse events… compared with alglucosidase alfa (low certainty).

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  RR 0.92 [0.61, 1.4]
  1 study · 100 participants
  Low

Alglucosidase alfa vs placebo

The review found no eligible studies for this question.

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Alglucosidase alfa vs placebo

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 90 participants
  Low

Alglucosidase alfa vs placebo

Alglucosidase alfa showed no clear difference in treatment‐related AEs compared with placebo (low certainty).

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  RR 0.94 [0.64, 1.39]
  1 study · 90 participants
  Low

Alglucosidase alfa plus clenbuterol vs alglucosidase alfa plus placebo

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 10 participants
  Very low

Alglucosidase alfa plus clenbuterol vs alglucosidase alfa plus placebo

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 11 participants
  Very low

Higher‐dose vs lower‐dose nicotine patch

Higher‐dose showed no clear difference in smoking cessation ‐ 42/44 mg versus 21/22 mg (24‐hour patches) compared with lower‐dose nicotine patch (moderate certainty).

• Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation 2023 · Cochrane Headline outcomes only
  RR 1.09 [0.93, 1.29]
  5 studies · 1655 participants
  Moderate
• Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation 2023 · Cochrane Headline outcomes only
  RR 1.19 [1, 1.41]
  3 studies · 3446 participants
  Moderate
• Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation 2023 · Cochrane Headline outcomes only
  RR 1.48 [1.06, 2.08]
  1 study · 537 participants
  Moderate

Higher‐dose vs lower‐dose nicotine patch

Higher‐dose showed no clear difference in overall SAEs ‐ 42/44 mg versus 21/22 mg (24 hr patches) compared with lower‐dose nicotine patch (low certainty).

• Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation 2023 · Cochrane Headline outcomes only
  RR 5.01 [0.87, 28.82]
  2 studies · 1023 participants
  Low
• Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 537 participants
  Low

Higher‐dose vs lower‐dose nicotine patch

Higher‐dose may leads to higher treatment withdrawals ‐ 42/44 mg versus 21/22 mg (24‐hour patches) compared with lower‐dose nicotine patch (low certainty).

• Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation 2023 · Cochrane Headline outcomes only
  RR 4.99 [1.6, 15.5]
  2 studies · 554 participants
  Low

Higher‐dose vs lower‐dose nicotine patch

Higher‐dose showed no clear difference in treatment withdrawals ‐ 21 mg versus 14 mg (24‐hour patches) compared with lower‐dose nicotine patch (low certainty).

• Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation 2023 · Cochrane Headline outcomes only
  RR 0.77 [0.36, 1.64]
  1 study · 537 participants
  Low

Intervention not reported

It is very uncertain whether the intervention changes smoking cessation ‐ oral spray versus gum (very low certainty).

• Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation 2023 · Cochrane Headline outcomes only
  RR 0.8 [0.29, 2.19]
  1 study · 75 participants
  Very low

Intervention not reported

It is very uncertain whether the intervention changes smoking cessation ‐ oral spray versus inhaler (very low certainty).

• Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation 2023 · Cochrane Headline outcomes only
  RR 2 [0.46, 8.73]
  1 study · 75 participants
  Very low

Intervention not reported

It is very uncertain whether the intervention changes smoking cessation ‐ gum versus inhaler (very low certainty).

• Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation 2023 · Cochrane Headline outcomes only
  RR 2.5 [0.53, 11.7]
  1 study · 50 participants
  Very low